A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-24-2113
Abstract: Abstract Purpose: Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present… read more here.
Keywords: ember study; cancer; breast cancer; her2 negative ... See more keywords